Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Biological: Denosumab
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2014-11-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12
- Registration Number
- NCT01869686
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Multiple Ascending Dose Study in Subjects With Type 2 Diabetes
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2015-11-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 86
- Registration Number
- NCT01856881
- Locations
- 🇺🇸
Research Site, Renton, Washington, United States
Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
Phase 3
Completed
- Conditions
- Hyperlipidemia and Mixed Dyslipidemia
- Interventions
- Biological: EvolocumabDrug: Standard of Care
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 3681
- Registration Number
- NCT01854918
- Locations
- 🇬🇧
Research Site, Whitby, United Kingdom
Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen
Phase 3
Completed
- Conditions
- Mixed DyslipidemiaPrimary Hypercholesterolemia
- Interventions
- Biological: Evolocumab AI/penBiological: Evolocumab Pre-filled Syringe
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 149
- Registration Number
- NCT01849497
- Locations
- 🇨🇦
Research Site, Pointe-Claire, Quebec, Canada
Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT01833754
- Locations
- 🇺🇸
Research Site, Orangeburg, South Carolina, United States
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)
- First Posted Date
- 2013-04-08
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 48
- Registration Number
- NCT01825785
Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer
Phase 3
Completed
- Conditions
- Castrate-resistant Prostate Cancer
- Interventions
- Biological: Denosumab
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2015-03-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 18
- Registration Number
- NCT01824342
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
Phase 3
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 955
- Registration Number
- NCT01818752
- Locations
- 🇺🇸
California Cancer Associates for Research & Excellence, Inc. (cCARE), Fresno, California, United States
🇨🇳Guangdong General Hospital, Guangzhou, Guangdong, China
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: PlaceboBiological: Evolocumab
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 970
- Registration Number
- NCT01813422
- Locations
- 🇬🇧
Research Site, Newcastle Upon Tyne, United Kingdom
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
Completed
- Conditions
- Chemotherapy-induced Febrile Neutropenia
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1007
- Registration Number
- NCT01813721
- Locations
- 🇪🇸
Research Site, Pamplona, Navarra, Spain
© Copyright 2025. All Rights Reserved by MedPath